Chelsea announces topline data from Phase II study of droxidopa in fibromyalgia.
M2 PHARMA-December 23, 2011-Chelsea announces topline data from Phase II study of droxidopa in fibromyalgia(C)2011 M2 COMMUNICATIONS
23 December 2011 - Chelsea Therapeutics International Ltd (NASDAQ:CHTP) on Thursday released topline data of a Phase II dose-finding trial intended to assess the safety and determine the potential therapeutic dose range of droxidopa monotherapy or droxidopa plus carbidopa for treatment of fibromyalgia.
The multi-centre, randomised, double-blind, placebo-controlled, dose response, factorial 12-arm parallel group trial, carried in the UK, assessed 120 patients equally randomised to receive droxidopa alone, carbidopa alone, droxidopa/carbidopa combination therapy or placebo.
The primary endpoint was the average reduction in pain as measured by the Short Form McGill Pain Questionnaire (SF-MPQ), with secondary goals including Fibromyalgia Index Questionnaire (FIQ) and Visual Analog Scale (VAS).
Topline results indicated a dose response with the highest dose of droxidopa, 600 mg TID, demonstrating a 6.2-point average improvement from a baseline score of 23.00 on the SF-MPQ at the end of the nine-week treatment period. This represents a 3.2 unit improvement over placebo on the SF-MPQ total pain score.
Although the trial was not intended to show statistical significance given the limited number of patients per arm, the results demonstrate a mean change in pain as measured by the visual analogue scale (VAS) of -1.64 for patients treated with droxidopa alone compared to a mean change of -0.90 for placebo. Assessment using FIQ showed patients treated with droxidopa alone demonstrated a mean change from baseline of -9.72 compared to -4.74 reported by patients in the placebo arm. Also, the trial showed that droxidopa as a monotherapy was more efficient than droxidopa/carbidopa combination therapy.
While overall dropouts in the trial were similar to the relatively high discontinuation rates seen in fibromyalgia studies, there were fewer dropouts in the monotherapy arm (29.2%) compared to placebo (46.7%). No serious adverse events occurred with either droxidopa monotherapy or droxidopa/carbidopa combination therapy.
NORTHERA (droxidopa) is Chelsea's most advanced drug candidate. It is an orally active synthetic precursor of norepinephrine originally developed to treat neurogenic orthostatic hypotension.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 23, 2011|
|Previous Article:||FDA advisory committee to review VIVUS application for Qnexa.|
|Next Article:||Olainfarm acquires 12 new pharmacies in Latvia.|